DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
-
Metergoline (HB1623)
Description:5-HT1/5-HT2 antagonist. Shows affinity for 5-HT6 and 5-HT7.
Purity:>98%
-
Mianserin hydrochloride (HB1658)
Description:Non-selective 5-HT2 receptor antagonist. Shows activity at other receptors.
Purity:>99%
-
±-Octopamine hydrochloride (HB2791)
Description:Invertebrate neurotransmitter. Chemogenetic DmOctβ1 receptor activator.
Purity:>99%
-
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
-
Perlapine (HB4889)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator
Purity:>98%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Water soluble.
Purity:>98%
